ACTIVATION OF NRF2 NEUROPROTECTIVE PATHWAYS FOR PARKINSON'S DISEASE

$31,486P51FY2007RRNIH

University Of Wisconsin-Madison, Madison WI

Investigators

Linked publications, trials & patents

Paper 39642160 Paper 38760983 Paper 38639635 Paper 38635668 Paper 38020807 Paper 37860906 Paper 37814073 Paper 37782672 Paper 37425681 Paper 37333300 Paper 37185781 Paper 37090620 Paper 36993525 Paper 36909458 Paper 36825014 Paper 36763214 Paper 36582226 Paper 36377872 Paper 35705631 Paper 35595058 Paper 35491543 Paper 35130312 Paper 33591361 Paper 33229035 Paper 33043166 Paper 32956357 Paper 32709417 Paper 32643223 Paper 32515834 Paper 32402468 Paper 32256496 Paper 32250358 Paper 32235848 Paper 32052009 Paper 31890736 Paper 31542153 Paper 31422797 Paper 31416800 Paper 31415241 Paper 31038661 Paper 31036928 Paper 30897187 Paper 30850342 Paper 30746836 Paper 30642966 Paper 30578305 Paper 30500414 Paper 30353260 Paper 30281932 Paper 30224552 Paper 29992471 Paper 29861167 Paper 29791856 Paper 29616024 Paper 29594415 Paper 29583085 Paper 29514073 Paper 29249843 Paper 29118125 Paper 28594774 Paper 28502529 Paper 28473378 Paper 28398464 Paper 28213784 Paper 28115506 Paper 28094793 Paper 27879435 Paper 27827365 Paper 27795809 Paper 27707919 Paper 27573879 Paper 27170760 Paper 27154414 Paper 27068622 Paper 27017056 Patent 9499786 Patent 8440461 Patent 8268620 Patent 8183038 Patent 8012751 Patent 7423010 Patent 6858582 Patent 6676972 Patent 6455073 Patent 6436437 Patent 6339060 Patent 6331388 Patent 6110741 Patent 6063759 Patent 6024977 Patent 5965519 Patent 5843780 Patent 5840674 Patent 5827819 Patent 5824548 Patent 5639852 Patent 5543391 Patent 5543390 Patent 5543389 Patent 5256641

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To explore if oral administration of pioglitazone can be used as neuroprotective therapy in Parkinson's disease.[unreadable] [unreadable] The identification of therapies aimed to slow or stop the progressive dopaminergic neuronal loss has become a priority for [unreadable] Parkinson's disease. Pioglitazone is an FDA approved, antidiabetic therapy found to have anti-inflammatory and anti-[unreadable] oxidant properties. During the last year, we completed the behavioral data collection for this study. We are now performing [unreadable] histological processing to assess if behavioral improvements are associated to nigrostriatal dopaminergic preservation. This [unreadable] research use WNPRC Animal Services and Assay Services.

View original record on NIH RePORTER →